The following adverse reactions have been identified during post approval use of Betaine
Anhydrous for Oral Solution. Because these reactions are reported voluntarily from a population
of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal
relationship to drug exposure.
Severe cerebral edema and hypermethioninemia have been reported within 2 weeks to 6 months
of starting Betaine Anhydrous for Oral Solution therapy, with complete recovery after
discontinuation of Betaine Anhydrous for Oral Solution. All patients who developed cerebral
edema had homocystinuria due to CBS deficiency and had severe elevation in plasma methionine
concentrations (range 1,000 to 3,000 microM). As cerebral edema has also been reported in
patients with hypermethioninemia, secondary hypermethioninemia due to betaine therapy has been
postulated as a possible mechanism of action
[see Warnings and Precautions (5.1)].
Other adverse reactions include: anorexia, agitation, depression, irritability, personality disorder,
sleep disturbed, dental disorders, diarrhea, glossitis, nausea, stomach discomfort, vomiting, hair
loss, hives, skin odor abnormalities, and urinary incontinence.